{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-049454","form_type":"8-K","ticker":"IPSC","cik":"0001850119","company_name":"Century Therapeutics, Inc.","filed_at":"2025-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.148143+00:00","generated_at":"2026-05-21T05:43:52.772530+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Century Therapeutics Q1 net income $76.6M on BMS termination revenue; CNTY-101 dosing started","bullets":["Net income of $76.6M vs $28.1M loss in Q1 2024, driven by $109.2M collaboration revenue from BMS deal termination.","Cash, equivalents, and securities $185.8M as of March 31, 2025, down from $220.1M; estimated runway into Q4 2026.","First patient dosed in Phase 1 CALiPSO-1 trial of CNTY-101 for autoimmune disease; clinical data expected by end of 2025.","CNTY-308 (CD19-targeted CAR-iT) on track to enter IND-enabling studies mid-2025.","R&D expenses increased to $26.6M from $23.4M due to clinical trial costs and preclinical program advancement."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-049454","json":"https://secwatch.observer/filing/0001104659-25-049454.json","markdown":"https://secwatch.observer/filing/0001104659-25-049454.md","text":"https://secwatch.observer/filing/0001104659-25-049454.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850119/000110465925049454/0001104659-25-049454-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850119/000110465925049454/tm2514971d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T05:43:52.772530+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}